AZTA
AzentaFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that the May reset clears the deck: Sample Management still has resilient recurring pockets, UK Biocentre expands European sample-management capacity, liquidity remains strong, and a cleaner portfolio after B Medical plus better Multiomics execution could rebuild margins from depressed expectations.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -1.0.
What can break
Automated Stores rework costs and higher excess-and-obsolete inventory reserves are already hurting gross margin and could persist if execution does not improve.
Momentum
6
Value
63
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.00 · Bull $26.00 · Bear $14.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $37.71
Why
Momentum6 · Δ7d +2.7
Value63 · Δ7d -1.0
Sentiment33 · Δ7d -10.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
6
34% active weight
Current posture
7d trendImproving
Δ7d
+2.7
Δ21d
+1.3
Value
63
32% active weight
Current posture
7d trendSoftening
Δ7d
-1.0
Δ21d
-2.3
Sentiment
33
33% active weight
Current posture
7d trendSoftening
Δ7d
-10.3
Δ21d
-17.6
Why this grade
Composite grade F. Momentum 6.4 / Value 62.9 / Sentiment 33.2
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.08B
Beta
1.34
Shares Out
45.99M
P/E (TTM)
67.2
P/S (TTM)
2.77
P/FCF (TTM)
42.90
Rev YoY
+5.2%
EPS YoY
+6706.0%
Gross Margin
+45.5%
Op Margin
-4.5%
Net Debt
-$339.41M
Current Ratio
2.98
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology